Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab

Journal of Rheumatology

Volumn 42, Issue 4, 2015, Pages 712-722

  Yokota, Shumpei ^a,b   Itoh, Yasuhiko ^a,c   Morio, Tomohiro ^a,d   Sumitomo, Naokata ^a,e   Daimaru, Kaori ^f   Minota, Seiji ^a,g  

^a Safety Evaluation Committee of Tocilizumab for JIA   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Infection associated hemophagocytic syndrome; Interleukins; Juvenile idiopathic arthritis; Macrophage activation syndrome; Postmarketing product surveillance; Tocilizumab

Indexed keywords

CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; GABEXATE MESILATE; HEPARIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; SOTHROMBOMODULIN ALFA; STEROID; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILL; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DISEASE REGISTRY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; LABORATORY TEST; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CODING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT RESPONSE; ARTHRITIS, JUVENILE; COMPLICATION; REGISTER; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MACROPHAGE ACTIVATION SYNDROME; MALE; REGISTRIES; YOUNG ADULT;

EID: 84940561271     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140288     Document Type: Article

References (45)

1. Cassidy JT, Petty RE. Juvenile idiopathic arthritis. In: Cassidy JT, Petty RE, Laxer R, Lindsley C, eds. Textbook of pediatric rheumatology, 6th ed. Philadelphia: WB Saunders; 2011:211-314.
2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49.
3. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
4. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005;28:231-8.
5. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
6. Imagawa T, Katakura S, Mori M, Aihara Y, Mitsuda T, Yokota S. [A case of macrophage activation syndrome developed with systemic juvenile idiopathic arthritis]. [Article in Japanese] Ryumachi 1997;37:487-92.
7. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998;20:247-59.
8. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
9. Yokota S, Kishimoto T. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol 2010;6:735-43.
10. Pharmaceuticals and Medical Devices Agency, Japan. [Actemra for intravenous infusion. Japanese product information, Tokyo]. [Article in Japanese; Internet. Accessed January 9, 2015. ] Available from: chugai-pharm. jp/hc/ss/pr/drug/act-via0080/pi/index. html
11. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
12. US Food and Drug Administration. Prescribing information of ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use. [Internet. Accessed December 23, 2014. ] Available from: www. accessdata. fda. gov/drugsatfda-docs/ label/2013/125276s092lbl. pdf.
13. European Medicines Agency. RoActemra: EPAR-Product Information. [Internet. Accessed December 23, 2014. ] Available from: www. ema. europa. eu/docs/en-GB/document-library/ EPARProduct-Information/human/000955/WC500054890. pdf.
14. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133-8.
15. Davì S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011;38:764-8.
16. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289-98.
17. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 1998;18:6353-64.
18. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996;129:750-4.
19. Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S, et al. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol 2012;95:428-33.
20. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009;10:387-92.
21. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819.
22. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83.
23. Nakajima S, Naruto T, Miyamae T, Imagawa T, Mori M, Nishimaki S, et al. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2009;19:42-6.
24. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol 2009;21:533-7.
25. Moradinejad MH, Ziaee V. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr 2011;63:459-66.
26. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
27. Sawar H, Espinoza LR, Gedalia A. Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis. J Rheumatol 2004;31:623.
28. Nádia EA, Carvalho JF, Bonfá E, Lotito AP, Silva CA. Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis. Isr Med Assoc J 2009;11:635-6.
29. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009;15:161-4.
30. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
31. Yanagimachi M, Naruto T, Miyamae T, Hara T, Kikuchi M, Hara R, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 2011;38:769-74.
32. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 2001;40:1285-92.
33. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003;15:587-90.
34. Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu TF, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care 2012;16:R52.
35. Kounami S, Yoshiyama M, Nakayama K, Okuda M, Okuda S, Aoyagi N, et al. Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol 2005;113:124-9.
36. Levi M. Disseminated intravascular coagulation: What's new? Crit Care Clin 2005;21:449-67.
37. Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 2011;17:568-73.
38. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002;30 Suppl 5:S220-4.
39. Harden LM, Rummel C, Luheshi GN, Poole S, Gerstberger R, Roth J. Interleukin-10 modulates the synthesis of inflammatory mediators in the sensory circumventricular organs: implications for the regulation of fever and sickness behaviors. J Neuroinflammation 2013;10:22.
40. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004;104:735-43.
41. Milner JD, Orekov T, Ward JM, Cheng L, Torres-Velez F, Junttila I, et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood 2010;116:2476-83.
42. Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011;208:1203-14.
43. Shuvaev VV, Muzykantov VR. Targeted modulation of reactive oxygen species in the vascular endothelium. J Control Release 2011;153:56-63.
44. Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 2004;50:689-98.
45. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology 2003;42:375-9.